• Explore /
  • Poster
  • / A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).

A randomized phase II study of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab for previously untreated, liver-limited metastatic colorectal cancer that is unsuitable for resection (ATOM trial).

Abstract Poster

Authors

null

Hiroyuki Uetake

Tokyo Medical and Dental University, Tokyo, Japan

Hiroyuki Uetake , Yasunori Emi , Takeharu Yamanaka , Kei Muro , Eiji Oki , Takao Takahashi , Takeshi Nagasaka , Etsuro Hatano , Hitoshi Ojima , Dai Manaka , Tetsuya Kusumoto , Yu Katayose , Toshiyoshi Fujiwara , Kazuhiro Yoshida , Michiaki Unno , Ichinosuke Hyodo , Naohiro Tomita , Kenichi Sugihara , Yoshihiko Maehara

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01836653

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 734)

DOI

10.1200/JCO.2018.36.4_suppl.734

Abstract #

734

Poster Bd #

H23

Abstract Disclosures

Similar Posters

First Author: Stefan Kasper

First Author: Yoshihito Ohhara

First Author: Hiroya Taniguchi

First Author: Kaori Hayashi